GLUE earnings analysis
What we found in GLUE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Monte Rosa Therapeutics (GLUE) reported Q1 2026 results with a significant decline in collaboration revenue, posting $4.2 million compared to $84.9 million in the same period last year. The company experienced a net loss of $44.5 million, worsening from a net income of $46.9 million in Q1 2025. Despite this, Monte Rosa maintains a robust liquidity position with $671 million in cash, sufficient to support operations through 2029.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Collaboration Revenue Drops
- Q1 2026 collaboration revenue fell to $4.2 million from $84.9 million in Q1 2025, a decrease of $80.7 million.
- Increased R&D Expenses
- R&D expenditures rose by 36.9% to $44.1 million in Q1 2026, up from $32.2 million in Q1 2025.
- Substantial Cash Reserves
- As of March 31, 2026, Monte Rosa had $671.2 million in cash and marketable securities, sufficient to fund operations into 2029.
- Operating Losses
- Operating loss for Q1 2026 was $50.0 million compared to operating income of $44.0 million in Q1 2025, indicating a decline in business performance.
- Net Loss Worsening
- Net loss of $44.5 million in Q1 2026, compared to net income of $46.9 million in Q1 2025, reflecting a significant downturn.
- Increased General and Administrative Costs
- General and administrative expenses rose 16.9% year-over-year to $10.2 million from $8.7 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High R&D Spending
- Research and development expenses increased to $44.1 million in Q1 2026, posing ongoing risks of escalating costs.
- Continued Operating Losses
- The company has incurred operating losses, with a total accumulated deficit of $521.7 million as of March 31, 2026.
- Revenue Dependency on Collaborations
- Q1 2026 revenue primarily depended on collaboration agreements with Roche and Novartis, but steep declines raise concerns about long-term sustainability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.36
- Gross margin
- 100%
- Operating margin
- -1207.1%
What they said about what is next.
No numeric guidance provided; management emphasizes ongoing challenges.
The filing reads worse than the one before it.
What came before.
- 10-K · March 17, 2026
- Monte Rosa (GLUE) presents significant clinical progress across its molecular glue pipeline (MRT-8102, MRT-2359, MRT-6160) and material collaboration agreements (Novartis $150M upfront; Roche $50M upfront) that…
- 10-Q · August 7, 2025
- Monte Rosa reported collaboration revenue of $23.194 million in Q2 2025 (vs. $4.695 million in Q2 2024) and GAAP diluted EPS of $(0.15), beating consensus. Operating loss narrowed to $(15.554) million from $(32.642)…
- 10-K · March 20, 2025
- Monte Rosa (GLUE) positions itself as a discovery-driven molecular glue degrader company built around its QuEENTM engine and a >50,000‑compound MGD library. The company secured material partner financings in 2024…
- 10-Q · August 10, 2023
- Monte Rosa reported a larger quarterly loss with net loss per share of $(0.71) for the three months ended June 30, 2023 compared with $(0.57) in the prior-year quarter, driven by higher R&D and G&A. The company stated…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GLUE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever